期刊名称:ACTA PHARMACEUTICA SINICA B
期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal

《药学学报》英文刊
《药学学报》英文刊(Acta Pharmaceutica Sinica B, APSB)是由中国药学会和中国医学科学院药物研究所共同主办,由《药学学报》编辑部与荷兰Elsevier B.V.出版公司合作出版的药学综合性英文期刊,是《药学学报》的系列期刊,创刊于2011年6月。其办刊宗旨是在世界药学领域的前沿和高端,搭建学术交流平台,引领和促进本学科的发展,向世界展示中国学者在药学领域研究的特色和成果,增强其国际影响力,推动我国药学事业的发展。期刊致力于发表药学科学和技术研究高端和前沿性的论文,快速报道药学科学基础研究和应用进展。报道范围覆盖化学药物、中药和天然药物、抗生素、蛋白质、多肽类药物、生物技术药物等的合成、分离鉴定、质量控制、药理、制剂、代谢等的原创性、创新性科研成果,栏目设综述与述评、研究论文、研究简报。
《药学学报》英文刊采用开放获取(OA)出版模式,全世界读者可以免费阅读和下载本刊发表的文章全文。期刊内容在世界上最大的出版平台ScienceDirect发布,论文内容传播速度快、范围广、影响大。采用国际通用的英文投审稿系统,1个月完成审稿,4-5个月上线出版。
《药学学报》英文刊目前不收取版面费和审稿费,稿酬从优;免费为所录用的非英语母语作者的文章进行语言润色修改,并根据文章质量及被引用情况,评选优秀论文,向优秀论文的作者颁发荣誉证书和奖金。
《药学学报》英文刊已被俄罗斯文摘和荷兰医学等数据库收录。2012年在中国科协优秀国际科技期刊奖的评选中荣获三等奖,并获创办英文科技期刊项目的支持。
Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a series of journal of Acta Pharmaceutica Sinica, which was founded in 1953, indexed in Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, Current Bibliography on Science and Technology, etc. It sponsored by Insititute of Materia Medica, Chineses Acedemy of Medical Sciences and Chinese Pharmaceutical Association, production and hosting by Elsevier B. V.
- Directory of Open Access Journals (DOAJ)
- Science Citation Index Expanded
- Scopus
- PubMed Central
- Ulrich's
- Chemical Abstracts
Instructions to Authors
Editorial Board
Editor-in-Chief
J.D. JiangInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaEmail J.D. Jiang
Associate Editors-in-Chief
Shi-Lin ChenInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
Xin-xin DingUniversity of Arizona, Tucson, USA
De-an GuoShanghai Inst. of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China
Long-qin HuRutgers University, Piscataway, New Jersey, USA
Rong-guang ShaoDepartment of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Jian-Gong ShiInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Xiao-liang WangInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Jian-ping YeLouisiana State University, Baton Rouge, USA
Qiang ZhangSch. of Pharmaceutical Sciences, Peking University, Beijing, China
Academic Consultants
David W. BoykinDept. of Chemistry, Georgia State University, Atlanta, Georgia, USA
Yung-Chi ChengDepartment of Pharmacology, Yale University, New Haven, Connecticut, USA
Jian DingShanghai Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai, China
Zong-ru GuoInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Chang-xiao LiuTianjin Institute of Pharmaceutical Research, Tianjin, China
Pei-gen XiaoInst. of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing, China
Bao-feng YangDept. of Pharmacology, Harbin Medical University, Harbin, Heilongjiang, China
De-quan YuInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Yong-su ZhenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College
Hong-hao ZhouCentral South University, Changsha, China
Tong-hui ZhouInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
|